Clinical Trials Partnership and Support

Clinical Trials Partnership and Support

MphaR Our Services Clinical Trials Partnership and Support

At MphaR, we provide comprehensive scientific expertise to strengthen every stage of your clinical trial—from early protocol development to effective collaboration with investigators and key opinion leaders. Our team of medical experts, scientific writers, and clinical specialists ensures your studies are strategically designed, scientifically sound, and executed with excellence.

Scientific Support in Clinical Trials

1. Steering Committees

We establish and manage highly qualified steering committees composed of global experts who provide scientific oversight, strategic advice, and critical decision-making throughout the study. MphaR facilitates all operations—from expert identification to meeting moderation—ensuring that your clinical development plan benefits from evidence-driven guidance and broad scientific alignment.

2. Investigator’s Meetings

We organise and deliver impactful investigator meetings that clearly communicate study objectives, operational expectations, and scientific rationale. Our team supports agenda creation, presentation development, live facilitation, and post-meeting follow-up to ensure site teams are aligned, engaged, and fully prepared for trial execution.

3. Protocol Writing

Our scientific writers develop clear, compliant, and robust clinical trial protocols tailored to your therapeutic area and study objectives. We ensure the protocol communicates the scientific rationale, methodology, patient pathways, and operational considerations in a way that supports regulatory approval and site implementation.

4. Protocol Assessment with KOLs

MphaR coordinates structured scientific reviews of your protocol with leading key opinion leaders. Their insights help refine study design, endpoint selection, inclusion/exclusion criteria, and feasibility. This early expert input strengthens study relevance, operational feasibility, and scientific credibility.

5. ISL Support

Our Investigator Science Liaisons (ISLs) serve as your scientific ambassadors, supporting trial sites with accurate information, addressing scientific questions, and fostering strong relationships between investigators and sponsors. ISL support enhances site engagement, encourages better recruitment performance, and ensures consistent scientific communication across regions.

6. Target Right Clinical Sites with MphaR Report

MphaR prepares tailor-made clinical site intelligence reports to support informed site selection and trial planning. Based on your specific disease area and study needs, our reports identify high-performing clinical sites with proven enrollment success in similar trials, highlight sites with competitive recruitment capabilities, and provide quality assessments informed by regulatory inspection history. This data-driven approach helps sponsors optimize site selection, reduce risks, and accelerate study

What HCPs and Medical Affairs Experts Tell About Working with Us

We work closely with HCPs and Medical Affairs experts worldwide. Here’s what they share about partnering with MphaR

Trusted by Industry Leaders

Medical Affairs Trends: Blog, Digest and Podcasts

Stay informed on emerging Medical Affairs trends with expert blog articles, and twice-monthly editions of our Medical Affairs Digest and podcasts series.

TrendWatch: Medical Affairs

Explore concise articles covering the latest trends and innovations in Medical Affairs

Latest Article

Virtual Reality in Medical Training: Immersive Learning Experiences

Contemporary medical education faces limitations in clinical exposure and resources, but virtual reality (VR) has emerged as a powerful solution. By recreating realistic and interactive clinical environments, VR allows healthcare professionals to actively engage in simulated experiences, enhancing skill refinement in a safe and scalable manner. Ultimately, this immersive technology promises profound improvements in training quality, competency development, and patient safety.

Sustainability in the Pharmaceutical Industry: A Greener Future for Healthcare

This blog post examines the environmental impact of the pharmaceutical industry, including high energy consumption and waste generation. It emphasizes the urgent need for sustainable practices, such as energy efficiency measures, water conservation, and waste reduction, to minimize environmental harm and ensure the industry’s long-term viability.

The Best Icebreakers for Virtual Meetings

The healthcare industry implemented different techniques to make interactions between pharmaceutical companies, healthcare professionals, and general physicians. Icebreakers for virtual meetings make it easy to connect with simple activities to build team camaraderie.

Bi-monthly Newsletter: Medical Affairs Digest

Your bi-monthly overview of essential Medical Affairs updates and emerging industry signals

Latest Newsletter
Bi-Monthly podcasts: Medical Affairs Voices

Listen to expert conversations exploring current trends and future directions in Medical Affairs

Precision Medicine in Oncology: Transforming Cancer Diagnostics Using AI Tools

In this episode, we uncover how artificial intelligence is transforming oncology, marking a shift from standardizedtreatments to precision medicine tailored to each patient’s genetic and molecular profile. From AI-powered imaging and digital pathology to genomic analysis and liquid biopsies, technology is reshaping how cancer is detected, understood, and treated. Hear how these innovations are driving earlier diagnoses, improving treatment accuracy, and empowering clinicians with insights once thought impossible. We also explore the ethical and practical challenges of integrating AI into cancercare and what it means for patients and providers alike. Join us as we look ahead to a future where AI doesn’t replace the human touch—it amplifies it, bringing us closer to truly personalized oncology care.

Leveraging AI and NLP to Transform Medical Information Systems in Medical Affairs

In this episode, we explore how artificial intelligence and natural language processing are reshaping how Medical Affairs teams manage, interpret, and apply vast volumes of unstructured medical information. From scientific literature and safety reports to advisory board insights and field intelligence, NLP is turning free text into structured, actionable knowledge—helping teams move faster while maintaining scientific rigor. Discover how NLP is being applied across literature intelligence, medical information systems, pharmacovigilance, and stakeholder engagement, and why human oversight remains essential in regulated medical environments. We also examine the risks, ethical considerations, and governance frameworks needed to ensure accuracy, transparency, and compliance. Join us as we look ahead to the evolution from language processing to true language understanding—and what this shift means for the future of Medical Affairs as a strategic, insight-driven function.

From Data to Dialogue — Strengthening Patient-Centricity Through Virtual Advisory Boards

In this episode, we examine how Virtual Advisory Boards are revolutionizing patient engagement, turning static data into meaningful dialogue that shapes real-world decisions. As patient-centricity becomes a defining principle in modern pharma, digital platforms are creating space for authentic collaboration between patients, caregivers, and industry leaders. Discover how virtual formats remove barriers to participation, ensure inclusivity, and make continuous patient input a practical reality. We’ll explore how the MphaR Virtual Advisory Board platform enables companies to integrate patient insights into trial design, treatment strategies, and beyond. Tune in as we explore how the future of patient engagement is being built—one conversation at a time—through innovation, empathy, and dialogue that truly puts patients at the center of healthcare.

Follow MphaR on Social Media:

MphaR Our Services Clinical Trials Partnership and Support

FAQs

Absolutely. Many partners send us their existing plan, and we strengthen the objectives, KPIs, tactics, and cross-functional alignment.
Yes. We often work with incomplete pipelines and help map the evidence gap and realistic timelines.
×

Thank you! Your message has been sent.

    Get Case Study

    Improving the treatment care of patients with Multiple Myeloma through regular digital connection between International, National Experts and haematologists in Europe

      Get Brochure